WINT Windtree Therapeutics

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company

Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree

The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc.

The executed agreement releases the parties from their reciprocal surviving obligations

WARRINGTON, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed a letter of intent with TESI (OTC: TESI), an environmental services company, and Windtree will receive $7.5 million in cash and TESI securities.

The companies were engaged on a potential acquisition of Titan Environmental Services, Inc., a waste management business with operations in Michigan. The companies mutually agreed to go their separate ways.

“Windtree is pleased to have signed this agreement, and we will focus our attention on other opportunities we have targeted as part of our corporate strategy to become a revenue generating company. We already have several companies where we are very close to LOI’s and we look forward to sharing more information on our progress in the very near future,” said Jed Latkin, Chief Executive Officer of Windtree.

See our public filings at .

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability.

Forward Looking Statements

The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business, and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact Information:

Eric Curtis



EN
13/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Windtree Therapeutics

 PRESS RELEASE

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash a...

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc. The executed agreement releases the parties from their reciprocal surviving obligations WARRINGTON, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtr...

 PRESS RELEASE

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue a...

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services Windtree is choosing to focus on environmental services and other revenue generating businesses – the Company will not move forward with the cryptocurrency treasury strategy Company continues to move forwar...

 PRESS RELEASE

Windtree Announces Istaroxime has been Chosen for a Plenary Session Pr...

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data was consistent with the profile seen in previous studies gives Windtree confidence to move forward with a global Phase 3 study WARRINGTON, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM...

 PRESS RELEASE

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C...

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials Cardiogenic shock is a severe presentation of heart failure and SCAI Stage C patients have low blood pressure and signs of organ damage due to low blood flow These data provide the Company confidence to move forward with a global Phase 3 trial WARRINGTON, Pa., Aug. 05, 2025 (...

 PRESS RELEASE

Windtree Therapeutics Announces Large Reduction of Preferred Series C ...

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17% since Windtree announced crypto treasury agreement with Build and Build Corp displaying the underlying demand for the coin globally WARRINGTON, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Wind...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch